New hope for kids with arthritis: Long-Term drug study launches

NCT ID NCT07553182

Recruiting now Disease control Sponsor: Alfasigma S.p.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This study is testing the long-term safety and effectiveness of the drug filgotinib in children and adolescents aged 8 to 17 with juvenile idiopathic arthritis. Participants must have already completed a previous filgotinib study and shown improvement. The goal is to see if the drug remains safe and helps control arthritis symptoms over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: filgotinib
What this could lead to: If successful, this could confirm filgotinib as a safe long-term treatment option for children and teens with juvenile idiopathic arthritis.
What could go wrong: This is an open-label extension study, so there is no placebo group for comparison. Long-term side effects are still being monitored, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for JUVENILE IDIOPATHIC ARTHRITIS (JIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis systemic-onset juvenile idiopathic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

JUVENILE IDIOPATHIC ARTHRITIS (JIA)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Asklepios Klinik Sankt Augustin GmbH
NOT_YET_RECRUITING

Sankt Augustin, 53757, Germany
Bicetre Hospital
RECRUITING

Le Kremlin-Bicêtre, 94270, France
Great Ormond Street Hospital for Children
NOT_YET_RECRUITING

London, WC1N 3JH, United Kingdom
Hamburger Zentrum für Kinder- und Jugendrheumatologie
RECRUITING

Hamburg, 22081, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.